Cargando…

Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates

Many different vaccine candidates against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of COVID-19, are currently approved and under development. Vaccine platforms vary from mRNA vaccines to viral-vectored vaccines, and several candidates have been shown to pro...

Descripción completa

Detalles Bibliográficos
Autores principales: van Doremalen, Neeltje, Fischer, Robert J., Schulz, Jonathan E., Holbrook, Myndi G., Smith, Brian J., Lovaglio, Jamie, Petsch, Benjamin, Munster, Vincent J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402814/
https://www.ncbi.nlm.nih.gov/pubmed/34452509
http://dx.doi.org/10.3390/v13081645
_version_ 1783745881522044928
author van Doremalen, Neeltje
Fischer, Robert J.
Schulz, Jonathan E.
Holbrook, Myndi G.
Smith, Brian J.
Lovaglio, Jamie
Petsch, Benjamin
Munster, Vincent J.
author_facet van Doremalen, Neeltje
Fischer, Robert J.
Schulz, Jonathan E.
Holbrook, Myndi G.
Smith, Brian J.
Lovaglio, Jamie
Petsch, Benjamin
Munster, Vincent J.
author_sort van Doremalen, Neeltje
collection PubMed
description Many different vaccine candidates against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of COVID-19, are currently approved and under development. Vaccine platforms vary from mRNA vaccines to viral-vectored vaccines, and several candidates have been shown to produce humoral and cellular responses in small animal models, non-human primates, and human volunteers. In this study, six non-human primates received a prime-boost intramuscular vaccination with 4 µg of mRNA vaccine candidate CV07050101, which encodes a pre-fusion stabilized spike (S) protein of SARS-CoV-2. Boost vaccination was performed 28 days post prime vaccination. As a control, six animals were similarly injected with PBS. Humoral and cellular immune responses were investigated at time of vaccination, and two weeks afterwards. No antibodies could be detected at two and four weeks after prime vaccination. Two weeks after boost vaccination, binding but no neutralizing antibodies were detected in four out of six non-human primates. SARS-CoV-2 S protein-specific T cell responses were detected in these four animals. In conclusion, prime-boost vaccination with 4 µg of vaccine candidate CV07050101 resulted in limited immune responses in four out of six non-human primates.
format Online
Article
Text
id pubmed-8402814
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84028142021-08-29 Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates van Doremalen, Neeltje Fischer, Robert J. Schulz, Jonathan E. Holbrook, Myndi G. Smith, Brian J. Lovaglio, Jamie Petsch, Benjamin Munster, Vincent J. Viruses Article Many different vaccine candidates against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of COVID-19, are currently approved and under development. Vaccine platforms vary from mRNA vaccines to viral-vectored vaccines, and several candidates have been shown to produce humoral and cellular responses in small animal models, non-human primates, and human volunteers. In this study, six non-human primates received a prime-boost intramuscular vaccination with 4 µg of mRNA vaccine candidate CV07050101, which encodes a pre-fusion stabilized spike (S) protein of SARS-CoV-2. Boost vaccination was performed 28 days post prime vaccination. As a control, six animals were similarly injected with PBS. Humoral and cellular immune responses were investigated at time of vaccination, and two weeks afterwards. No antibodies could be detected at two and four weeks after prime vaccination. Two weeks after boost vaccination, binding but no neutralizing antibodies were detected in four out of six non-human primates. SARS-CoV-2 S protein-specific T cell responses were detected in these four animals. In conclusion, prime-boost vaccination with 4 µg of vaccine candidate CV07050101 resulted in limited immune responses in four out of six non-human primates. MDPI 2021-08-19 /pmc/articles/PMC8402814/ /pubmed/34452509 http://dx.doi.org/10.3390/v13081645 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
van Doremalen, Neeltje
Fischer, Robert J.
Schulz, Jonathan E.
Holbrook, Myndi G.
Smith, Brian J.
Lovaglio, Jamie
Petsch, Benjamin
Munster, Vincent J.
Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates
title Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates
title_full Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates
title_fullStr Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates
title_full_unstemmed Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates
title_short Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates
title_sort immunogenicity of low-dose prime-boost vaccination of mrna vaccine cv07050101 in non-human primates
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402814/
https://www.ncbi.nlm.nih.gov/pubmed/34452509
http://dx.doi.org/10.3390/v13081645
work_keys_str_mv AT vandoremalenneeltje immunogenicityoflowdoseprimeboostvaccinationofmrnavaccinecv07050101innonhumanprimates
AT fischerrobertj immunogenicityoflowdoseprimeboostvaccinationofmrnavaccinecv07050101innonhumanprimates
AT schulzjonathane immunogenicityoflowdoseprimeboostvaccinationofmrnavaccinecv07050101innonhumanprimates
AT holbrookmyndig immunogenicityoflowdoseprimeboostvaccinationofmrnavaccinecv07050101innonhumanprimates
AT smithbrianj immunogenicityoflowdoseprimeboostvaccinationofmrnavaccinecv07050101innonhumanprimates
AT lovagliojamie immunogenicityoflowdoseprimeboostvaccinationofmrnavaccinecv07050101innonhumanprimates
AT petschbenjamin immunogenicityoflowdoseprimeboostvaccinationofmrnavaccinecv07050101innonhumanprimates
AT munstervincentj immunogenicityoflowdoseprimeboostvaccinationofmrnavaccinecv07050101innonhumanprimates